Alk-Abello A/S

ALK B

Equity

ISIN DK0061802139 / Valor 117689788

Nasdaq Copenhagen Equities (2025-11-21)

DKK 227.40-2.07%

Alk-Abello A/S
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Alk-Abello A/S is a Danish pharmaceutical company specializing in the development and production of allergy immunotherapy products. The company is committed to advancing long-term allergy treatment and aims to establish a leading position in the management of food allergies and anaphylaxis. Alk-Abello's strategic focus includes expanding its portfolio of respiratory allergy tablets and enhancing its pediatric coverage. The company is also exploring partnerships to accelerate the commercial adoption of its products across various markets. By prioritizing innovation and optimizing its operations, Alk-Abello seeks to address unmet needs in adjacent allergic conditions. The company emphasizes cultivating its organizational capabilities to foster a high-performance culture and improve access to allergy care.

Summarized from source with an LLMView SourceSector: Healthcare

Q4 2024 Revenue

Revenue rose by 11% to DKK 1,499 million, supported by strong performance in Europe, while North America and International markets saw no growth this quarter.

Q4 2024 Tablet Sales

Tablet sales increased by 17% to DKK 795 million, with Europe contributing a 32% growth driven by new patients and better pricing.

Q4 2024 Operating Profit (EBIT)

Operating profit modestly improved to DKK 205 million, reflecting investments in R&D and Sales & Marketing, alongside one-off costs associated with the in-licensing of neffy® and optimization efforts in China.

2024 Full-Year Revenue

For the full year 2024, revenue grew by 15% to DKK 5,537 million, with all product lines experiencing growth.

2024 Full-Year EBIT

EBIT for the full year reached DKK 1,091 million, up 65% from the previous year, with an EBIT margin increasing to 20% from 14%.

2025 Financial Outlook

Alk-Abelló A/S expects revenue to grow by 9-13% in 2025, driven by volume growth across regions and product groups, particularly tablets. The EBIT margin is anticipated to improve by 5 percentage points to around 25%, supported by revenue growth, improved gross margins, and further optimizations.

Summarized from source with an LLMView Source

Key figures

47.0%1Y

124%3Y

118%5Y

Performance

31.6%1Y

38.0%3Y

37.3%5Y

Volatility